Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution
 Back to Details

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Mark J. Ratain and Everett E. Vokes.

 
Connection Strength
  
 
 
0.667
  
  1. Rudin CM, Liu W, Desai A, Karrison T, Jiang X, Janisch L, Das S, Ramirez J, Poonkuzhali B, Schuetz E, Fackenthal DL, Chen P, Armstrong DK, Brahmer JR, Fleming GF, Vokes EE, Carducci MA, Ratain MJ. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol. 2008 Mar 01; 26(7):1119-27.
    View in: PubMed
    Score: 0.092
  2. Innocenti F, Vokes EE, Ratain MJ. Irinogenetics: what is the right star? J Clin Oncol. 2006 May 20; 24(15):2221-4.
    View in: PubMed
    Score: 0.081
  3. Desai AA, Kindler HL, Taber D, Agamah E, Mani S, Wade-Oliver K, Ratain MJ, Vokes EE. Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer. Cancer Chemother Pharmacol. 2005 Oct; 56(4):421-6.
    View in: PubMed
    Score: 0.076
  4. Ryan CW, Vogelzang NJ, Vokes EE, Kindler HL, Undevia SD, Humerickhouse R, André AK, Wang Q, Carr RA, Ratain MJ. Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies. Clin Cancer Res. 2004 Jul 01; 10(13):4406-11.
    View in: PubMed
    Score: 0.071
  5. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramírez J, Rudin CM, Vokes EE, Ratain MJ. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004 Apr 15; 22(8):1382-8.
    View in: PubMed
    Score: 0.070
  6. Vogelzang NJ, Karrison T, Stadler WM, Garcia J, Cohn H, Kugler J, Troeger T, Giannone L, Arrieta R, Ratain MJ, Vokes EE. A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma. Cancer. 2004 Jan 01; 100(1):65-71.
    View in: PubMed
    Score: 0.069
  7. Ryan CW, Vokes EE, Vogelzang NJ, Janisch L, Kobayashi K, Ratain MJ. A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer. Cancer Chemother Pharmacol. 2002 Jul; 50(1):1-5.
    View in: PubMed
    Score: 0.061
  8. Foster CC, Fleming GF, Karrison TG, Liao CY, Desai AV, Moroney JW, Ratain MJ, Nanda R, Polite BN, Hahn OM, O'Donnell PH, Vokes EE, Kindler HL, Hseu R, Janisch LA, Dai J, Hoffman MD, Weichselbaum RR, Pitroda SP, Chmura SJ, Luke JJ. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518.
    View in: PubMed
    Score: 0.058
  9. Reizine N, Vokes EE, Liu P, Truong TM, Nanda R, Fleming GF, Catenacci DVT, Pearson AT, Parsad S, Danahey K, van Wijk XMR, Yeo KJ, Ratain MJ, O'Donnell PH. Implementation of pharmacogenomic testing in oncology care (PhOCus): study protocol of a pragmatic, randomized clinical trial. Ther Adv Med Oncol. 2020; 12:1758835920974118.
    View in: PubMed
    Score: 0.056
  10. Bhatta SS, Wroblewski KE, Agarwal KL, Sit L, Cohen EE, Seiwert TY, Karrison T, Bakris GL, Ratain MJ, Vokes EE, Maitland ML. Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis. Oncologist. 2013; 18(8):965-70.
    View in: PubMed
    Score: 0.033
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.